DWM
VRTX icon

Dakota Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Dakota Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Hold
0
– -$2.9M – 639
2022
Q3 		– Hold
0
– – – 102
2022
Q2 		– Hold
0
– – – 49

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dakota Wealth Management's VRTX Position: Q2 2026 in Review

Dakota Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q2 2026, buying an estimated $14.6K and bringing the position to 2,862 shares worth $1.42M. The position accounts for 0.03% of the portfolio, ranked #369.

Dakota Wealth Management first reported a position in VRTX in Q4 2014 and has held it in 43 quarters since. The position peaked at $16M in Q3 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Dakota Wealth Management held 2,862 shares of Vertex Pharmaceuticals worth $1.42M as of Q2 2026.
  • Dakota Wealth Management bought 33 Vertex Pharmaceuticals shares in Q2 2026, an estimated $14.6K.
  • Vertex Pharmaceuticals made up 0.03% of Dakota Wealth Management's portfolio in Q2 2026, its #369 holding.
  • Dakota Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 43 quarters since.
  • Dakota Wealth Management's Vertex Pharmaceuticals position peaked at $16M in Q3 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Dakota Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.